Infection with HTLV-II in humans is normally determined by the ability to detect antibodies to the virus. However, it is possible that infectious virus is present prior to the appearance of those antibodies. The purpose of this study is to determine if infectious HTLV-II or HTLV-II genome can be detected in a high risk population (intravenous drug users) in the absence of detectable antibodies to the virus. Polymerase chain reaction techniques will be used to detect HTLV-II DNA and RNA in blood samples from donors. The laboratory in which these studies will be performed is being established currently and it is anticipated that results will be available in coming years.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Intramural Research (Z01)
Project #
1Z01BP003010-01
Application #
3770424
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Bureau of Health Planning and Resources Development
Department
Type
DUNS #
City
State
Country
United States
Zip Code